Parschauer Karah Herdman 4
4 · Ultragenyx Pharmaceutical Inc. · Filed Mar 3, 2025
Insider Transaction Report
Form 4
Parschauer Karah Herdman
EVP and Chief Legal Officer
Transactions
- Sale
Common Stock
2025-02-27$42.75/sh−760$32,490→ 54,991 total - Award
Stock Option (Right to Buy)
2025-03-01+26,074→ 26,074 totalExercise: $42.92Exp: 2035-03-01→ Common Stock (26,074 underlying) - Sale
Common Stock
2025-02-27$42.93/sh−2,230$95,734→ 55,751 total - Award
Common Stock
2025-03-01+14,494→ 69,690 total
Footnotes (4)
- [F1]Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date
- [F2]Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
- [F3]Includes 205 shares acquired on October 31, 2024 under the Company's Amended and Restated Employee Stock Purchase Plan
- [F4]On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date.